ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the overall safety and tolerability of ARC1779, a therapeutic oligonucleotide
("aptamer") in patients with three types of von Willebrand Factor related platelet disorders.